Annals of Hematology

, Volume 86, Issue 4, pp 239–244

Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F

  • C. Steimle
  • U. Lehmann
  • S. Temerinac
  • Ph. S. Goerttler
  • H. Kreipe
  • G. Meinhardt
  • H. Heimpel
  • H. L. Pahl
Original Article

DOI: 10.1007/s00277-006-0214-1

Cite this article as:
Steimle, C., Lehmann, U., Temerinac, S. et al. Ann Hematol (2007) 86: 239. doi:10.1007/s00277-006-0214-1

Abstract

Three consecutive polycythemia vera (PV) patients were analyzed before and during pegylated-interferon (rIFNα) treatment for the following markers: (1) granulocyte and CD34+ cell clonality, (2) Jak2V617F expression, (3) PRV-1 mRNA overexpression, and (4) Epo-independent colony (EEC) growth. Before rIFNα therapy, all patients displayed clonal hematopoiesis, 100% Jak2V617F expression as well as PRV-1 overexpression, and EEC growth. After rIFNα treatment, all three patients demonstrated polyclonal hematopoiesis. Nonetheless, Jak2V617F expression, PRV-1 overexpression, and EEC-growth remained detectable, albeit at lower levels. We conclude that reemergence of polyclonal hematopoiesis after rIFNα treatment may be achieved in a substantial proportion of patients. However, this does not constitute elimination of the PV clone. These data demonstrate the usefulness of novel markers in monitoring minimal residual disease and caution against discontinuation of rIFNα treatment after hematologic remission. Long-term follow-up of large patient cohorts is required to determine whether rIFNα treatment can cause complete molecular remissions in PV.

Keywords

Polycythemia vera Pegylated-interferon (rIFNα) treatment Granulocyte and CD34+ cell clonality Jak2V617F expression PRV-1 mRNA overexpression EEC growth 

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • C. Steimle
    • 1
  • U. Lehmann
    • 2
  • S. Temerinac
    • 1
  • Ph. S. Goerttler
    • 1
  • H. Kreipe
    • 2
  • G. Meinhardt
    • 3
  • H. Heimpel
    • 4
  • H. L. Pahl
    • 1
  1. 1.Department of Experimental AnaesthesiologyUniversity Hospital Freiburg, Center for Clinical ResearchFreiburgGermany
  2. 2.Institute of PathologyMedizinische Hochschule HannoverHannoverGermany
  3. 3.Department of Hematology/Oncology, Klinikum InnenstadtLudwig-Maximilians-Universität MünchenMünchenGermany
  4. 4.Department of Hematology and OncologyUniversity Hospital UlmUlmGermany

Personalised recommendations